Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic dual-plasmid HBV DNA vaccine + lamivudine in HBeAg-positive chronic hepatitis B
CTR20170675Phase 2Completed
- Sponsor
- Guangzhou Baiyunshan Baidi Biopharmaceutical
- Start
- Sep 2017
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of therapeutic double-plasmid hepatitis b virus deoxyribonucleic acid vaccine in Chronic hepatitis B (CHB), sponsored by Guangzhou Baiyunshan Baidi Biopharmaceutical. Started Sep 2017; status: completed.
02
Drugs
therapeutic double-plasmid hepatitis b virus deoxyribonucleic acid vaccine
03
Conditions
Chronic hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20170675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170675.